Drugs / GamEMab
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT03428347 | Mar → Dec 2018 | — | Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | GamEMab | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03428347 ↗ |
| Modality | Monoclonal antibody | “drug for emergency prevention of Ebola based on recombinant monoclonal antibodies” NCT03428347 ↗ |